

## Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: The STARRT-AKI Investigators. Timing of initiation of renal-replacement therapy in acute kidney injury. *N Engl J Med* 2020;383:240-51. DOI: 10.1056/NEJMoa2000741

## **Tables of Contents of the Supplementary Appendix:**

<b>1. Trial Personnel</b>	3
1.1 International Steering Committee	3
1.2 Writing Committee	4
1.3 Independent Data Safety Monitoring Board	6
1.4 Study Coordinating Centres and Senior Research Personnel	7
1.5 Acknowledgements	8
1.6 Sites, Investigators and Research Personnel	9
<b>2. Endorsement and Funding</b>	17
<b>3. Data Management and Monitoring</b>	18
<b>4. Data Sharing Statement</b>	19
<b>5. Supplemental Tables</b>	20
Table S1: Results of the planned interim analyses.	20
Table S2: Eligibility criteria.	21
Table S3: Pre-planned exploratory analyses of death at 90-days (primary outcome) and renal-replacement therapy dependence at 90-days (secondary outcome).	22
Table S4: Summary of reasons for exclusion of patients randomized and found non-eligible patients.	23
Table S5: Expanded characteristics by allocated treatment-strategy.	24
Table S6: Characteristics at renal-replacement therapy initiation.	26
Table S7: Characteristics of the initial renal-replacement therapy prescription.	27
Table S8: Summary of pre-planned inverse probability weighted and multinomial analyses for renal-replacement therapy dependence at 90-days.	28
Table S9: Cause of death.	29
Table S10: All-cause mortality at 90-days across pre-specified sub-groups.	30
Table S11: All-cause mortality at 90-days across countries.	31
<b>6. Supplemental Figures</b>	33
Figure S1: Screening and recruitment algorithm.	33
Figure S2: Participant flow diagram.	34
Figure S3: Time to renal-replacement therapy initiation accounting for the competing risk of death.	35
Figure S4: Kaplan-Meier survival estimates of the probability of survival to 90-days including patients lost to follow-up.	36
Figure S5: Heterogeneity of treatment effect by deciles of SAPS II score in fully adjusted model.	37

## **1. Trial Personnel:**

**1.1 International Steering Committee:** The Steering Committee's full names and academic degrees are as follows: **Sean M. Bagshaw** (Co-Chair)\* M.D., M.Sc., Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, and Alberta Health Services, Edmonton, AB, Canada, **Ron Wald** (Co-Chair)\* M.D.C.M., M.P.H., Division of Nephrology, St. Michael's Hospital and the University of Toronto and the Li Ka Shing Knowledge Institute, Toronto, ON, Canada; **Neill K.J. Adhikari**, M.D.C.M., M.Sc., Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, ON, Canada; **Ruminder Bajwa**<sup>§</sup>, Baxter, Mississauga, Canada; **Rinaldo Bellomo**, M.D., Ph.D., Department of Intensive Care, Austin Hospital, Melbourne, Department of Intensive Care, Royal Melbourne Hospital, Melbourne, School of Medicine, The University of Melbourne, Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia **Didier Dreyfuss**, M.D., Department of Critical Care Medicine, Hôpital Louis Mourier, Paris, France and INSERM Unit UMR S1155 Sorbonne Université and Université de Paris, Paris, France; **Bin Du**, M.D., Ph.D., Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing, China; **Martin P. Gallagher**, M.D., Ph.D., The George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, NSW, Australia; **Stéphane Gaudry**, M.D., Ph.D., Department of Critical Care Medicine, Hôpital Avicenne, Bobigny, France and INSERM Unit UMR S1155 Sorbonne Université and Université de Léonard de Vinci, France; **Eric A. Hoste**, M.D., Ph.D., Department of Critical Care Medicine, University of Ghent, Ghent Belgium; **François Lamontagne**, M.D., Department of Medicine, Université de Sherbrooke, Centre de recherche du CHU de Sherbrooke, Sherbrooke, QC, Canada; **Michael Joannidis**, M.D., Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria; **Kathleen D. Liu**, M.D., Ph.D., Divisions of Critical Care Medicine and Nephrology, University of California San Francisco, San Francisco, California, USA; **Daniel F. McAuley**, M.D., The Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and The Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, United Kingdom; **Shay P. McGuinness**, M.D., Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland and Medical Research Institute of New Zealand, Wellington; **Alistair D. Nichol**, M.D., Department of Critical Care Medicine University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin, Ireland/Monash University, Melbourne, Australia; **Marlies Ostermann**, M.D., Department of Critical Care Medicine, King's College London, Guy's & St Thomas' Hospital, London, United Kingdom; **Paul M. Palevsky**, M.D., Division of Nephrology, University of Pittsburgh, Pittsburgh and VA Pittsburgh Healthcare System, Pittsburgh, PA, USA; **Haibo Qiu**, M.D., Ph.D., Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing, China; **Ville Pettilä**, M.D., Ph.D., Department of Intensive Care Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; **Antoine G. Schneider**, M.D., Department of Intensive Care, Centre Hospitalier Universitaire Vaudois, Lausanne,

Switzerland; **Orla M. Smith**, R.N., Ph.D., Department of Critical Care and Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada; **Suvi Vaara**, M.D., Ph.D., Department of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; **Matthew Weir**, M.D., Division of Nephrology, London Health Sciences Centre, London, ON, Canada.

\* Drs. Bagshaw and Wald have contributed equally to this work.

§non-voting

**1.2 Writing Committee:** The writing committee's full names and academic degrees are as follows: \***Sean M. Bagshaw**, M.D., M.Sc., Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton, AB, Canada; \***Ron Wald**, M.D.C.M., M.P.H., Division of Nephrology, St. Michael's Hospital and the University of Toronto and the Li Ka Shing Knowledge Institute, Toronto, ON, Canada; **Neill K.J. Adhikari**, M.D.C.M., M.Sc., Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Canada; **Rinaldo Bellomo**, M.D., Ph.D., Department of Intensive Care, Austin Hospital, Melbourne, Australia; Department of Intensive Care, Royal Melbourne Hospital, Melbourne, Australia; School of Medicine, The University of Melbourne, Melbourne, Australia, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; **Bruno R. da Costa**, Ph.D., Applied Health Research Centre, Li Ka Shing Knowledge Institute of St. Michael's Hospital, University of Toronto, Toronto, Canada; **Didier Dreyfuss**, M.D., Department of Critical Care Medicine, Hôpital Louis Mourier, Paris, France and INSERM Unit UMR S1155 Sorbonne Université and Université de Paris, Paris, France; **Bin Du**, M.D., Ph.D., Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing, China; **Martin P. Gallagher**, M.D., Ph.D., The George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, NSW, Australia; **Stéphane Gaudry**, M.D., Ph.D., Department of Critical Care Medicine, Hôpital Avicenne, Bobigny, France and INSERM Unit UMR S1155 Sorbonne Université and Université de Léonard de Vinci, France; **Eric A. Hoste**, M.D., Ph.D., Department of Intensive Care, University of Ghent, Ghent Belgium; **François Lamontagne**, M.D., Department of Medicine, Université de Sherbrooke, Centre de recherche du CHU de Sherbrooke, Sherbrooke, QC, Canada; **Michael Joannidis**, M.D., Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria; **Giovanni Landoni**, M.D., Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan, Italy; **Kathleen D. Liu**, M.D., Ph.D., Divisions of Intensive Care and Nephrology, University of California San Francisco, San Francisco, California, USA; **Daniel F. McAuley**, M.D., The Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and The Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, United Kingdom; **Shay P. McGuinness**, M.D., Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland and Medical Research Institute of New Zealand, Auckland, New Zealand; **Javier A. Neyra**,

M.D., Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington, Kentucky, USA; **Alistair D. Nichol**, M.D., Department of Critical Care Medicine, University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin, Ireland/Monash University, Melbourne, Australia; **Marlies Ostermann**, M.D., Department of Critical Care Medicine, King's College London, Guy's & St Thomas' Hospital, London, United Kingdom; **Paul M. Palevsky**, M.D., Division of Nephrology, University of Pittsburgh, Pittsburgh and VA Pittsburgh Healthcare System, Pittsburgh, PA, USA; **Ville Pettilä**, M.D., Ph.D., Department of Intensive Care Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; **Haibo Qiu**, M.D., Ph.D., Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing, China; **Jean-Pierre Quenot**, M.D., Department of Critical Care Medicine, Hôpital Universitaire François Mitterrand, and Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer - Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, and Centre d'Investigation Clinique – Epidemiologie Clinique, CHU Dijon-Bourgogne and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon; **Bram Rochweg**, M.D., Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON, Canada; **Antoine G. Schneider**, M.D., Department of Intensive Care, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; **Orla M. Smith**, R.N., Ph.D., Department of Critical Care and Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada; **Fernando Thomé**, M.D., Ph.D., Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; **Kevin E. Thorpe**, M.Math., Applied Health Research Centre, Li Ka Shing Knowledge Institute of St. Michael's Hospital, University of Toronto, Toronto, Canada; **Suvi Vaara**, M.D., Ph.D., Department of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; **Matthew A. Weir**, M.D., Division of Nephrology, London Health Sciences Centre, London, ON, Canada; **Amanda Y. Wang**, M.D. Ph.D., The George Institute for Global Health and Concord Clinical School, The University of Sydney, Sydney, NSW, Australia; **Paul Young**, MBChB, Ph.D., Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand, Wellington, New Zealand; **Alexander Zarbock**, M.D., Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany.

\* Drs. Bagshaw and Wald have contributed equally to this work.

### **1.3 Independent Data Safety Monitoring Board (DSMB):**

**Kathryn Rowan** (Chair), Ph.D., Intensive Care National Audit & Research Centre (ICNARC), London, United Kingdom; **Dean A. Fergusson**, Ph.D., Ottawa Health Research Institute, University of Ottawa, Ottawa, ON, Canada; **Stuart L. Goldstein**, M.D., Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; **David Harrison**, Ph.D., Intensive Care National Audit & Research Centre (ICNARC), London, United Kingdom; **Timothy S. Walsh**, M.D., University of Edinburgh, Edinburgh, United Kingdom. The DSMB charter is available at: <https://www.ualberta.ca/critical-care/research/current-research/starrtaki/documents> (Accessed Feb 4, 2020).

#### **1.4 Study Coordinating Centres and Senior Research Personnel:**

*Canada and Worldwide:* The Applied Health Research Centre (AHRC), Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada.

Rekha Thomas; Sydney Currier; Hae Jin (Angela) Kwak; Jhansi L. Saranu; Nikita Chavda; Jessica Marchese; Joyce Deng; Magdalena Zaporowska; Janice Jansen-Periera; Karen Pope, Judith Hall; Brian Kirkham; Diana Yan.

*Australia and China:* The George Institute for Global Health (Sydney) and George Clinical (Beijing). Erika Dempsey; Namrata Nath Kumar; Jade Newman; Qin Wang; Bridie Vaughan; Ming Yue; Yanru Yan. Prince of Wales Hospital, Sydney. Prof. Zoltan Endre.

*France:* Unité de Recherche Clinique, Hôpital Bichat, Paris, France. Aline Dechanet.

*New Zealand:* Medical Research Institute of New Zealand. Raulle Sol Cruz.

*United Kingdom:* Guy's & St Thomas' Hospital NHS Foundation, London, UK. Gill Arbane.

### **1.5 Acknowledgements:**

Dr. S.M. Bagshaw is supported by a Canada Research Chair in Critical Care Nephrology. Prof A.D. Nichol is supported by a Health Research Board of Ireland Clinical Trial Network award. Dr. A.G. Schneider is supported by a grant from Fondation Leenaards. Dr. S. Vaara is supported by a grant for Clinical Researchers from the Academy of Finland. Dr. P. Young was supported by a Clinical Practitioner Research Fellowship from the Health Research Council of New Zealand.

We would like to thank Dr. Damon Scales and Dr. Robert Fowler for their careful review of this manuscript.



**1.6 Sites, Investigators and Research Personnel:** (alphabetically by country)

<b>Institution</b>	<b>Investigators and Research Personnel</b>
<b>AUSTRALIA</b>	
Austin Health	Rinaldo Bellomo; Glenn M. Eastwood, Leah Peck; Helen Young
Princess Alexandra Hospital	Peter Kruger; Gordon Laurie; Emma Saylor; Jason Meyer; Ellen Venz; Krista Wetzig
Western Health	Craig French; Forbes McGain; John Mulder; Gerard Fennessy; Sathyajith Koottayi; Samantha Bates; Miriam Towns; Rebecca Morgan; Anna Tippet
The Alfred Hospital	Andrew Udy; Chris Mason; Elisa Licari; Dashiell Gantner; Jason McClure; Alistair Nichol; Phoebe McCracken; Jasmin Board; Emma Martin; Shirley Vallance; Meredith Young; Chelsey Vladic; Steve McGloughlin
Royal Prince Alfred Hospital	David Gattas; Heidi Buhr; Jennifer Coles; Debra Hutch; James Wun
Nepean Hospital	Louise Cole; Christina Whitehead; Julie Lowrey; Kristy Masters; Rebecca Gresham
Sunshine Coast University Hospital	Victoria Campbell; David Gutierrez; Jane Brailsford; Loretta Forbes; Lauren Murray; Teena Maguire
Barwon Health	Martina NiChonghaile; Neil Orford; Allison Bone; Tania Elderkin; Tania Salerno
Bendigo Health	Tim Chimunda; Jason Fletcher; Emma Broadfield; Sanjay Porwal; Cameron Knott; Catherine Boschert; Julie Smith
Ballarat Health	Angus Richardson; Dianne Hill
Eastern Health	Graeme Duke; Peter Oziemski; Santiago Cegarra; Peter Chan; Deborah Welsh; Stephanie Hunter; Owen Roodenburg; John Dyett; Nicos Kokotsis; Max Moser; Yang Yang; Laven Padayachee; Joseph Vetro; Himangsu Gangopadhyay; Melissa Kaufman
The Northern Hospital	Angaj Ghosh; Simone Said
Flinders Medical Centre	Alpesh Patel; Shailesh Bihari; Elisha Matheson; Xia Jin; Tapaswi Shrestha; Kate Schwartz
Concord Repatriation General Hospital	Martin P. Gallagher; Rosalba Cross; Winston Cheung; Helen Wong; Mark Kol; Asim Shah; Amanda Y. Wang
Royal North Shore Hospital	Celia Bradford; Pierre Janin; Simon Finfer; Naomi Diel; Jonathan Gatward; Naomi Hammond; Anthony Delaney; Frances Bass; Elizabeth Yarad
St. Vincent's Hospital	Hergen Buscher; Claire Reynolds; Nerilee Baker
<b>AUSTRIA</b>	
Department of Internal Medicine, Medical University Innsbruck	Michael Joannidis; Romuald Bellmann; Andreas Peer; Julia Hasslacher; Paul Koglberger; Sebastian Klein; Klemens Zotter; Anna Brandtner; Armin Finkenstedt; Adelheid Ditlbacher; Frank Hartig

Department of General and Surgical Critical Care Medicine, Medical University Innsbruck	Dietmar Fries; Mirjam Bachler; Bettina Schenk; Martin Wagner
Department of Internal Medicine, Medical University of Graz	Philipp Eller
Medical University of Vienna	Thomas Staudinger; Esther Tiller; Peter Schellongowski; Andja Bojic
<b>BELGIUM</b>	
Ghent University Hospital	Eric A. Hoste; Stephanie Bracke; Luc De Crop; Daisy Vermeiren
<b>BRAZIL</b>	
Hospital de Clínicas de Porto Alegre	Fernando Thome; Bianca Chiella; Lucia Fendt; Veronica Antunes
<b>CANADA</b>	
Centre de recherche de l'Hôpital Maisonneuve-Rosemont	Jean-Philippe Lafrance
Centre Hospitalier Universitaire de Sherbrooke	François Lamontagne; Frédérick D'Aragon; Charles St-Arnaud; Michael Mayette; Éline Carbonneau; Joannie Marchand; Marie-Hélène Masse; Marilène Ladouceur
CHU de Québec-Université Laval Research Center	Alexis F. Turgeon; François Lauzier; David Bellemare; Charles Langis Francoeur; Guillaume LeBlanc; Gabrielle Guilbault; Stéphanie Grenier; Eve Cloutier; Annick Boivin; Charles Delisle-Thibault; Panagiota Giannakouros; Olivier Costerousse
Centre hospitalier de l'Université de Montréal	Jean-François Cailhier; François-Martin Carrier; Ali Ghamraoui; Martine Lebrasseur; Fatna Benettaib; Maya Salamé; Dounia Boumahni
Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec	Ying Tung Sia; Jean-François Naud; Isabelle Roy
Foothills Medical Centre	Henry T. Stelfox; Stacey Ruddell; Braden J. Manns
Grey Nuns Community Hospital	Shelley Duggan; Dominic Carney; Jennifer Barchard
Hamilton Health Sciences	Richard P. Whitlock; Emilie Belley-Cote; Nevena Savija; Alexandra Sabev; Troy Campbell; Thais Creary; Kelson Devereaux; Shira Brodutch
Health Sciences Centre, University of Manitoba	Claudio Rigatto; Bojan Paunovic; Owen Mooney; Anna Glybina; Oksana Harasemiw; Michelle Di Nella
Health Sciences North	John Harmon; Navdeep Mehta; Louis Lakatos; Nicole Haslam
Institut Universitaire de Cardiologie et de Pneumologie de Québec	Francois Lellouche; Mathieu Simon; Ying Tung; Patricia Lizotte; Pierre-Alexandre Bourchard
Juravinski Hospital	Bram Rochweg; Tim Karachi; Tina Millen
Kingston Health Sciences Centre	John Muscedere; David Maslove; J. Gordon Boyd; Stephanie Sibley; John Drover; Miranda Hunt; Ilinca Georgescu
Lakeridge Health	Randy Wax; Ilan Lenga; Kavita Sridhar; Andrew Steele; Kelly Fusco; Taneera Ghate; Michael Tolibas; Holly Robinson
London Health Sciences Centre, University Hospital	Matthew A. Weir; Ravi Taneja

London Health Sciences Centre, Victoria Hospital	Ian M. Ball; Amit X. Garg; Eileen Campbell; Athena Ovsenek
Mazankowski Alberta Heart Institute	Sean M. Bagshaw, Sean van Diepen, Nadia Baig
McGill University Health Centre	Sheldon Magder; Han Yao; Ahsan Alam; Josie Campisi
Misericordia Community Hospital	Erika MacIntyre; Ella Rokosh; Kimberly Scherr
Mount Sinai Hospital	Stephen Lapinsky; Sangeeta Mehta; Sumesh Shah
Peter Lougheed Centre	Daniel J. Niven; Henry T. Stelfox; Stacey Ruddell
Red Deer Regional Hospital	Michael Russell; Kym Jim; Gillian Brown; Kerry Oxtoby; Adam Hall; Luc Benoit; Colleen Sokolowski
Regina Qu'Appelle Health Authority	Bhanu Prasad; Shelley Giebel
Royal Alexandra Hospital	Demetrios J. Kutsogiannis; Patricia Thompson; Tayne Thompson
St. Joseph's Health Centre	Robert Cirone; Kanthi Kavikondala
St. Joseph's Healthcare	Mark Soth; France Clarke; Alyson Takaoka
St. Michael's Hospital	Ron Wald; David Mazer; Karen Burns; Jan Friedrich; David Klein; Gyan Sandhu; Marlene Santos; Imrana Khalid; Jennifer Hodder
St. Paul's Hospital	Peter Dodek; Najib Ayas; Victoria Alcuaz
Sturgeon Community Hospital	Gabriel Suen; Oleksa Rewa; Gurmeet Singh; Sean Norris; Neil Gibson; Castro Arias; Aysha Shami; Celine Pelletier
Sunnybrook Health Sciences Centre	Neill K.J. Adhikari; Alireza Zahirieh; Andre Amaral; Nicole Marinoff; Navjot Kaur; Adic Perez; Jane Wang
Surrey Memorial Hospital	Gregory Haljan; Christopher Condin
The Ottawa Hospital	Lauralyn McIntyre; Brigette Gomes; Rebecca Porteous; Irene Watpool; Swapnil Hiremath; Edward Clark
Toronto General Hospital	Margaret S. Herridge; Felicity Backhouse
Toronto Western Hospital	M. Elizabeth Wilcox; Karolina Walczak
Trillium Health Partners	Vincent Ki; Asheer Sharman; Martin Romano
University of Alberta Hospital	Sean M. Bagshaw; R.T. Noel Gibney; Adam S. Romanovsky; Lorena McCoshen; Nadia Baig
Vancouver Island Health Authority	Gordon Wood; Daniel Ovakim; Fiona Auld; Gayle Carney
<b>CHINA</b>	
Beijing Friendship Hospital, Capital Medical University	Meili Duan; Xiaojun Ji; Dongchen Guo; Zhili Qi; Jin Lin; Meng Zhang; Lei Dong; Jingfeng Liu; Pei Liu; Deyuan Zhi; Guoqiang Bai; Yu Qiu; Ziqi Yang; Jing Bai; Zhuang Liu; Haizhou Zhuang; Haiman Wang; Jian Li; Mengya Zhao; Xiao Zhou
Guizhou Provincial People's Hospital	Xianqing Shi; Banning Ye; Manli Liu; Jing Wu; Yongjian Fu; Dali Long; Yu Pan; Jinlong Wang; Huaxian Mei; Songsong Zhang; Mingxiang Wen; Enyu Yang; Sijie Mu; Jianquan Li; Tingting Hu
Henan Provincial People's Hospital	Bingyu Qin; Min Li; Cunzhen Wang; Xin Dong; Kaiwu Wang; Haibo Wang; Jianxu Yang
Peking Union Medical College Hospital	Bin Du; Chuanyao Wang

Peking University First Hospital	Dongxin Wang; Nan Li
Renmin Hospital of Wuhan University	Zhui Yu; Song Xu; Lan Yao; Guo Hou; Zhou Liu; Liping Lu; Yingtao Lian
Shandong Provincial Hospital	Chunting Wang; Jichen Zhang; Ruiqi Ding; Guoqing Qi; Qizhi Wang; Peng Wang; Zhaoli Meng; Man Chen; Xiaobo Hu
The First Affiliated Hospital of Bengbu Medical College	Xiandi He; Shibing Zhao; Lele Hang; Rui Li; Suhui Qin; Kun Lu; Shijuan Dun; Cheng Liu; Qi Zhou; Zhenzhen Chen; Jing Mei
The First Affiliated Hospital of Xiamen University	Minwei Zhang; Hao Xu; Jincan Lin
The First Affiliated Hospital of Xi'An Jiaotong University	Qindong Shi; Lijuan Fu; Qinjing Zeng; Hongye Ma; Jinqi Yan; Lan Gao; Hongjuan Liu; Lei Zhang; Hao Li; Xiaona He; Jingqun Fan; Litao Guo; Yu Liu; Xue Wang; Jingjing Sun
The First Hospital of Jilin University	Zhongmin Liu; Juan Yang; Lili Ding; Lulu Sheng; Xingang Liu
Wuxi People's Hospital	Jie Yan; Quhui Wang; Yifeng Wang; Dan Zhao
Xiangya Hospital Central South University	Shuangping Zhao; Chenghuan Hu; Jing Li; Fuxing Deng
Zhongda Hospital Southeast University	Haibo Qui; Yi Yang; Min Mo; Chun Pan; Changde Wu; Yingzi Huang; Lili Huang; Airan Liu
<b>FINLAND</b>	
Helsinki University Hospital	Ville Pettilä; Suvi T. Vaara; Anna-Maija Korhonen; Sanna Törnblom; Sari Sutinen; Leena Pettilä; Jonna Heinonen; Eliria Lappi; Taria Suhonen
Tampere University Hospital	Sari Karlsson; Sanna Hoppu; Ville Jalkanen; Anne Kuitunen; Markus Levoranta; Jaakko Långsjö; Sanna Ristimäki; Kaisa Malila; Anna Wootten; Simo Varila
Turku University Hospital	Mikko J Järvisalo; Outi Inkinen; Satu Kentala; Keijo Leivo; Paivi Haltia
<b>FRANCE</b>	
Hôpital Louis Mourier	Didier Dreyfuss; Jean-Damien Ricard; Jonathan Messika; Abirami Tiagarajah; Malo Emery; Aline Dechanet; Coralie Gernez; Damien Roux
Centre Hospitalier Départemental La Roche-Sur-Yon	Laurent Martin-Lefevre; Maud Fiancette; Isabelle Vinatier; Jean Claude Lacherade; Gwenhaël Colin; Christine Lebert; Marie-Ange Azais; Aihem Yehia; Caroline Pouplet; Matthieu Henry-Lagarrigue; Amélie Seguin; Laura Crosby
Medical Intensive Care Unit, Amiens University Hospital	Julien Maizel; Dimitri Titeca-Beauport
Hôpital Pitie-Salpetriere	Alexandre Demoule; Julien Mayaux; Martin Dres; Elise Morawiec; Maxens Decalvele; Suela Demiri; Morgane Faure; Clémence Marios; Maxime Mallet; Marie Amélie Ordon; Laura Morizot; Marie Cantien; François Pousset
Hôpital Avicenne/Hôpital Jean Verdier	Stéphane Gaudry; Florent Poirson; Yves Cohen
Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de Médecine Intensive – Réanimation	Laurent Argaud; Martin Cour; Laurent Bitker; Marie Simon; Romain Hernu; Thomas Baudry; Sylvie De La Salle

CH De Bourg-en-Bresse – Fleyriat	Adrien Robine; Nicholas Sedillot; Xavier Tchenio; Camille Bouisse; Sylvie Roux
CHRU de Nîmes	Saber Davide Barbar; Rémi Trusson
Rouen University Hospital	Fabienne Tamion; Steven Grangé; Dorothee Carpentier
CH Sud Francilien	Guillaume Chevrel; Luis Ensenyat-Martin; Sophie Marque
CHU Dijon	Jean-Pierre Quenot; Pascal Andreu; Auguste Dargent; Audrey Large
CH Le Mans - Réanimation Medico - Chirurgicale	Nicolas Chudeau; Mickael Landais; Benoit Derrien; Jean Christophe Callahan; Christophe Guitton; Charlène Le Moal; Alain Robert
CHU Nantes/Service d'Anesthésie - Réanimation chirurgicale HD PTMC	Karim Asehnoune; Raphaël Cinotti; Nicolas Grillot; Dominique Demeure
Germon et Gauthier Hospital – Béthune	Christophe Vinsonneau; Imen Rahmani; Mehdi Marzouk; Thibault Dekeyser; Caroline Sejourne; Mélanie Verlay; Fabienne Thevenin; Lucie Delecolle
Centre Hospitalier Lens	Didier Thevenin
Clermont Ferrand	Bertrand Souweine; Elisabeth Coupeuz; Mireille Adda
CH de Dieppe	Jean-Pierre Eraldi; Antoine Marchalot
Hôpital Henri Mondor	Nicolas De Prost; Armand Mekontso Dessap; Keyvan Razazi
Hôpital Civil	Ferhat Meziani; Julie Boisrame-Helms; Raphael Clere-Jehl; Xavier Delabranche; Christine Kummerlen; Hamid Merdji; Alexandra Monnier; Yannick Rabouel; Hassene Rahmani; Hayat Allam; Samir Chenaf; Vincenta Franja
CHU de Pointe à Pitre	Bertrand Pons; Michel Carles; Frédéric Martino; Régine Richard
André Mignot	Benjamin Zuber; Guillaume Lacave
CHU de Nantes	Karim Lakhali; Bertrand Rozec; Hoa Dang Van
Centre de Beaumont sur Oise	Éric Boulet
Centre Hospitalier René Dubos Pontoise	Fouad Fadel; Cedric Cleophax; Nicolas Dufour; Caroline Grant; Marie Thuong
Hotel Dieu – Service de Médicale	Jean Reignier; Emmanuel Canet; Laurent Nicolet
CHR Orleans	Thierry Boulain; Mai-Anh Nay; Dalila Benzekri; François Barbier; Anne Bretagnol; Toufik Kamel; Armelle Mathonnet; Grégoire Muller; Marie Skarzynski; Julie Rossi; Amandine Pradet; Sandra Dos Santos; Aurore Guery; Lucie Muller; Luis Felix
CH Lyon Sud – Pierre Benite	Julien Bohé; Guillaume Thiéry
Universite de Paris, Hopital Europeen Georges Pompidou	Nadia Aissaoui; Damien Vimpere; Morgane Commeureuc; Jean-Luc Diehl; Emmanuel Guerot
Hopital Pitie Salpetriere	Alain Combes; Ania Nieszkowska; Paul Masi
<b>GERMANY</b>	
Klinikum Coburg	Orfeas Liangos; Monika Wittig
University Hospital Münster	Alexander Zarbock; Mira Küllmar; Thomas van Waegeningh; Nadine Rosenow
<b>IRELAND</b>	
St. Vincent's University Hospital	Alistair D. Nichol; Kathy Brickell; Peter Doran; Patrick T. Murray
<b>ITALY</b>	
IRCCS San Raffaele Scientific Institute	Giovanni Landoni; Rosalba Lembo; Alberto Zangrillo; Giacomo Monti; Margherita Tozzi; Matteo Marzaroli; Gaetano Lombardi

San Carlo Hospital	Gianluca Paternoster; Michelangelo Vitiello
<b>NEW ZEALAND</b>	
Auckland Hospital Cardiovascular Surgical Intensive Care Unit	Shay McGuinness; Rachael Parke; Magdalena Butler; Eileen Gilder; Keri-Anne Cowdrey; Samantha Wallace; Jane Hallion; Melissa Woolett; Philippa Neal; Karina Duffy; Stephanie Long
Department of Critical Care Medicine, Auckland Hospital	Colin McArthur; Catherine Simmonds; Yan Chen; Rachael McConnochie; Lynette Newby
Christchurch Hospital	David Knight; Seton Henderson; Jan Mehrtens; Stacey Morgan; Anna Morris; Kymbalee Vander Hayden; Tara Burke
Hawke's Bay Hospital	Matthew Bailey; Ross Freebairn; Lesley Chadwick; Penelope Park; Christine Rolls; Liz Thomas
Rotorua Hospital	Ulrike Buehner; Erin Williams
Taranaki Hospital	Jonathan Albrett; Simon Kirkham; Carolyn Jackson
Tauranga Hospital	Troy Browne; Jennifer Goodson; David Jackson; James Houghton; Owen Callender; Vicki Higson; Owen Keet; Clive Dominy
Wellington Hospital	Paul Young; Anna Hunt; Harriet Judd; Cassie Lawrence; Shaanti Olatunji; Yvonne Robertson; Charlotte Latimer-Bell; Deborah Hendry; Agnes Mckay-Vucago; Nina Beehre; Eden Lesona; Leanlove Navarra; Chelsea Robinson
Whangarei Hospital	Ryan Jang; Andrea Junge; Bridget Lambert
<b>SWITZERLAND</b>	
Centre Hospitalier Universitaire Vaudois	Antoine G. Schneider; Michel Thibault; Philippe Eckert; Sébastien Kissling; Erietta Polychronopoulos; Elettra Poli; Marco Altarelli; Madeleine Schnorf; Samia Abed Mallaird
Hôpitaux Universitaires de Genève	Claudia Heidegger; Aurelie Perret; Philippe Montillier; Frederic Sangla; Seigenthaler Neils; Aude De Watteville
<b>UNITED KINGDOM</b>	
Barking, Havering and Redbridge University Hospitals NHS Trust	Mandeep-Kaur Phull; Aparna George; Nauman Hussain; Tatiana Pogreban
Barnsley Hospital NHS Foundation Trust	Steve Lobaz; Alison Daniels; Mishell Cunningham; Deborah Kerr; Alice Nicholson
Buckinghamshire Healthcare NHS Trust	Pradeep Shanmugasundaram; Judith Abrams; Katarina Manso; Geraldine Hambrook; Elizabeth McKerrow; Juvy Salva; Stephen Foulkes
Cardiff and Vale University Health Board	Matthew Wise; Matt Morgan; Jenny Brooks; Jade Cole; Tracy Michelle Davies; Helen Hill; Emma Thomas
Chelsea and Westminster Hospital NHS Foundation Trust	Marcela Vizcaychipi; Behrad Baharlo; Jaime Carungcong; Patricia Costa; Laura Martins
East Kent NHS Trust	Ritoo Kapoor; Tracy Hazelton; Angela Moon; Janine Musselwhite
Golden Jubilee National Hospital, NHS Scotland	Ben Shelley; Philip McCall
Guy's and St. Thomas' NHS Foundation Trust	Marlies Ostermann; Gill Arbane; Aneta Bociek; Martina Marotti; Rosario Lim; Sara Campos; Neus Grau Novellas; Armando Cennamo; Andrew Slack; Duncan Wyncoll; Luigi Camporota; Simon Sparkes; Rosalinde Tilley

University Hairmyres Hospital, NHS Lanarkshire	Austin Rattray; Gayle Moreland; Jane Duffy; Elizabeth McGonigal
King's College Hospital NHS Foundation Trust	Philip Hopkins; Clare Finney; John Smith; Harriet Noble; Hayley Watson; Claire-Louise Harris; Emma Clarey; Eleanor Corcoran
Leeds Teaching Hospital NHS Foundation Trust	James Beck; Clare Howcroft; Nora Youngs; Elizabeth Wilby; Bethan Ogg
Lincoln County Hospital – United Lincolnshire Hospitals NHS Foundation Trust	Adam Wolverson; Sandra Lee; Susie Butler; Maryanne Okubanjo; Julia Hindle
Liverpool University Hospitals NHS Foundation Trust	Ingeborg Welters; Karen Williams; Emily Johnson; Julie Patrick-Heselton; David Shaw; Victoria Waugh
Milton Keynes University Hospital NHS Foundation Trust	Richard Stewart; Esther Mwaura; Lynn Wren; Louise Mew; Sara-Beth Sutherland; Jane Adderley
University Hospital Monklands, NHS Lanarkshire	Jim Ruddy; Margaret Harkins
NHS Grampian	Callum Kaye; Teresa Scott; Wendy Mitchell; Felicity Anderson; Fiona Willox
North Tees and Hartlepool Foundation NHS Trust	Vijay Jagannathan; Michele Clark; Sarah Purv
Nottingham University Hospital - Queen's Medical Centre	Andrew Sharman; Megan Meredith; Lucy Ryan; Louise Conner; Cecilia Peters; Dan Harvey
Queen Elizabeth Hospital - Lewisham and Greenwich NHS Trust	Ashraf Roshdy; Amy Collins
Queen Elizabeth University Hospital	Malcolm Sim; Steven Henderson
Royal Bournemouth & Christchurch Hospitals NHS Trust	Nigel Chee; Sally Pitts; Katie Bowman; Maria Dilawershah; Luke Vamplew; Elizabeth Howe
Royal Brompton and Harefield NHS Foundation Trust	Paula Rogers; Clara Hernandez; Clara Prendergast; Jane Benton; Alex Rosenberg
Royal Surrey County Hospital NHS Foundation Trust	Lui G. Forni; Alice Grant; Paula Carvelli
Sheffield Teaching Hospitals NHS Foundation Trust	Ajay Raithatha; Sarah Bird; Max Richardson; Matthew Needham; Claire Hirst
St. George's University Hospitals NHS Foundation Trust	Jonathan Ball; Susannah Leaver; Luisa Howlett; Carlos Castro Delgado; Sarah Farnell-Ward; Helen Farrah; Geraldine Gray; Gipsy Joseph; Francesca Robinson
St. Helen's and Knowsley Teaching Hospitals NHS Trust	Ascanio Tridente; Clare Harrop; Karen Shuker
University Hospital Ayr, NHS Ayrshire & Arran	Derek McLaughlan; Judith Ramsey; Sharon Meehan
University Hospital Lewisham, Lewisham and Greenwich NHS Trust	Bernd Oliver Rose; Rosie Reece-Anthony; Babita Gurung
University Hospitals Birmingham NHS Foundation Trust	Tony Whitehouse; Catherine Snelson; Tonny Veenith; Andy Johnston; Lauren Cooper; Ron Carrera; Karen Ellis; Emma Fellows; Samanth Harkett; Colin Bergin; Elaine Spruce; Liesl Despy; Stephanie Goundry; Natalie Dooley; Tracy Mason; Amy Clark

University Hospitals Coventry and Warwickshire NHS Trust	Gemma Dignam; Geraldine Ward
Warwick Hospital, South Warwickshire NHS Trust	Ben Attwood; Penny Parsons; Sophie Mason
St. Richard's Hospital, Western Sussex Hospitals NHS Foundation Trust	Michael Margarson; Jenny Lord; Philip McGlone
Worthing Hospital, Western Sussex Hospitals NHS Foundation Trust	Luke E. Hodgson; Indra Chadbourn; Raquel Gomez; Jordi Margalef
York Teaching Hospital NHS Foundation Trust	Rinus Pretorius; Alexandra Hamshere; Joseph Carter; Hazel Cahill; Lia Grainger; Kate Howard; Greg Forshaw; Zoe Guy
<b>UNITED STATES</b>	
Mayo Clinic, Rochester	Kianoush B. Kashani; Robert C. Albright Jr.; Amy Amsbaugh; Anita Stoltenberg; Alexander S. Niven
Rhode Island Hospital	Matthew Lynch; AnnMarie O'Mara; Syed Naeem; Sairah Sharif; Joyce McKenney Goulart
The Miriam Hospital	Matthew Lynch; AnnMarie O'Mara; Syed Naeem; Sairah Sharif; Joyce McKenney Goulart
University of Alabama at Birmingham	Ashita Tolwani; Claretha Lyas; Laura Latta
University of Florida	Azra Bihorac; Haleh Hashemighouchani; Philip Efron; Matthew Ruppert; Julie Cupka; Sean Kiley; Joshua Carson; Peggy White; George Omalay; Sherry Brown; Laura Velez; Alina Marceron
University of Kentucky	Javier A. Neyra; Juan Carlos Aycinena; Madona Elias; Victor M. Ortiz-Soriano; Caroline Hauschild; Robert Dorfman



## **2. Endorsement and Funding:**

The STARRT-AKI trial was endorsed by the Canadian Critical Care Trials Group (CCCTG), the Canadian Nephrology Trials Network (CNTN), the Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS-CTG), the United Kingdom Critical Care Research Group (UKCCRG), the Irish Critical Care Clinical Trials Group/Network (ICC-CTG/N) and the European Society of Intensive Care Medicine (ESICM).

The study was funded by the following sources: Canadian Institutes of Health Research (Open Operating Grant MOP142296 and Project Grant 389635); Canadian Institutes of Health Research in partnership with Baxter (Industry-Partnered Operating Grant IPR 139081); National Health Medical Research Council of Australia (Project Grant 1127121); the Health Research Council of New Zealand (Project Grant 17/204) and the National Institutes of Health Research Health Technology Assessment Program (United Kingdom) (Reference Number: 17/42/74). In 2017, the STARRT-AKI was adopted by the National Institutes for Health Research (United Kingdom) as a portfolio study.

The Canadian Critical Care Trials Group is supported by a Canadian Institutes of Health Research Community Development Program Grant 138094.

The funding organizations and partners were not involved in the design, implementation or management of the trial. All analyses were undertaken independent of the funding organizations and partners. This manuscript was written by the Co-Chairs and the members of the Writing Committee and the decision to submit for publication was independent of the funding organizations and partners.

### **3. Data Management and Monitoring:**

Database programming and data management took place at the central coordinating centre located at the Applied Health Research Centre (AHRC), Toronto, ON, Canada. A manual of operations and data dictionary that defined each data element to be collected was developed. (Available at: <https://www.ualberta.ca/critical-care/research/current-research/starrtaki/documents>) (Accessed February 4, 2020).

Several procedures were undertaken to ensure data quality:

- A site initiation visit, delivered in person or by webinar, was performed by the STARRT-AKI trial Co-Chairs (Sean M Bagshaw; Ron Wald) or their delegates for local research personnel (i.e., research coordinators and investigators) prior to study commencement.
- The coordinating centre regularly generated a series of data management reports to ensure data quality and completeness. All queries emanating from these reports were addressed by local investigators and research personnel.
- Remote monitoring and source data verification. This monitoring was performed to verify critical variables related to eligibility, informed consent, data completeness and primary and secondary outcomes and was performed in a random sample of 2 of the first 5 patients enrolled at each site and subsequently, for 10% of patients randomized at each site. This was performed in Austria, Belgium, Brazil, Canada, Finland, Germany, Ireland, Italy, and the United States.
- Onsite monitoring and source data verification. This monitoring was to verify critical variables related eligibility, informed consent, data completeness and primary and secondary outcomes. This was performed in Australia, China, France, New Zealand, Switzerland and the United Kingdom.
- Further email and teleconference communication supplemented data management and data monitoring activities.

The detailed summary of the data management and monitoring plan is available at: <https://www.ualberta.ca/critical-care/research/current-research/starrtaki/documents> (Accessed February 4, 2020).

#### **4. Data Sharing Statement:**

The STARRT-AKI data sharing statement will generally align with the data sharing policy of The George Institute for Global Health (<https://www.georgeinstitute.org/data-sharing-policy>).

The STARRT-AKI Co-Chairs and Steering Committee support the view that research data generated from publicly-funded research should be made available for sharing to enhance public well-being, to maximize the potential knowledge gained, to reduce redundant research and to facilitate scientific discovery and innovation.

Data sharing will be for the purposes of medical research and under the auspices of the consent under which the data were originally gathered.

De-identified individual participant data collected during the STARRT-AKI trial will be shared beginning two years after the publication of the primary and secondary analyses, with no end date.

Data will be made available to qualified researchers who provide a detailed and methodologically sound proposal with specific aims that are clearly outlined.

To gain access, qualified researchers will need to sign a data sharing and access agreement and will need to confirm that data will only be used for the purpose for which data access was granted.

Proposals should be directed to the trial Co-Chairs via email: [bagshaw@ualberta.ca](mailto:bagshaw@ualberta.ca) and [Ron.Wald@unityhealth.to](mailto:Ron.Wald@unityhealth.to).

## 5. Supplemental Tables:

<b>Table S1: Results of the planned interim analyses.</b>					
<b>Primary outcome (90-day mortality)</b>	<b>Date</b>	<b>Accelerated</b>	<b>Standard</b>	<b>Relative Risk (95% CI)</b>	<b>P-value</b>
<b>First interim analysis</b>	Dec 21, 2017	146/369	152/371	0.97 (0.81 to 1.15)	0.70
<b>Second interim analysis</b>	Aug 20, 2018	307/732	308/720	0.98 (0.87 to 1.11)	0.75
<b>Third interim analysis</b>	Mar 29, 2019	460/1079	464/1072	0.98 (0.89 to 1.09)	0.76

Abbreviations: CI = confidence interval

Proportions are presented as number of patients with primary outcome (numerator)/total number of patients randomized (denominator). All analyses are unadjusted.

The first interim analysis was performed when 25% (740 patients) reached the 90-day outcome. The second interim analysis was performed when 50% (1452 patients) reached the 90-day outcome. The third interim analysis was performed when 75% (2151 patients) reached the 90-day outcome.

The O'Brien-Fleming stopping rule was used with negligible impact on the final type 1 error rate.

<b>Table S2: Eligibility criteria.</b>
<b><i>Inclusion criteria are (all must be fulfilled):</i></b>
1. Age $\geq 18$ years on the day of eligibility screening
2. Admission to an intensive care unit
3. Evidence of kidney dysfunction: serum creatinine $\geq 100$ $\mu\text{mol/L}$ [1.13 mg/dL] [women] or $\geq 130$ $\mu\text{mol/L}$ [1.47 mg/dL] [men] based on last bloodwork available prior to screening that has not declined by $>27$ $\mu\text{mol/L}$ [0.3 mg/dL] compared to the highest value recorded in the preceding 48 hours
4. Evidence of severe acute kidney injury based on at least ONE of the following three criteria: i) 2-fold increase in serum creatinine from baseline; OR ii) current serum creatinine is $\geq 354$ $\mu\text{mol/L}$ [4.0 mg/dL] with a minimum increase of 27 $\mu\text{mol/L}$ [0.3 mg/dL] from the baseline serum creatinine; OR iii) urine output $<6$ mL/kg in the prior 12 hours
<b><i>Exclusion criteria are (none may be present):</i></b>
1. Potassium at time of screening $>5.5$ mmol/L
2. Bicarbonate at time of screening $<15$ mmol/L
3. Presence of a drug overdose or dialyzable toxin that necessitates renal-replacement therapy
4. Lack of commitment to provide renal-replacement therapy as part of philosophy of care
5. Receipt of any renal-replacement therapy in the preceding 2 months
6. Kidney transplant within the past 365 days
7. Known advanced chronic kidney disease defined by an estimated glomerular filtration rate (eGFR) $<20$ mL/min/1.73 m <sup>2</sup>
8. Presence or strong clinical suspicion of renal obstruction, rapidly progressive glomerulonephritis, vasculitis, thrombotic microangiopathy or acute interstitial nephritis
If the patient fulfilled all <i>inclusion criteria</i> and none of the aforementioned <i>exclusion criteria</i> had been identified, the patient was deemed to be <i>provisionally eligible</i> . The next step was to ascertain whether the most responsible clinician(s) (the attending critical care physician and where relevant, the attending nephrologist) were in a position of clinical equipoise with respect to the two renal-replacement therapy initiation strategies that the provisionally eligible patient would receive if he/she was randomized. This was performed in practice by ascertaining the presence of the following two exclusion criteria:
9. Clinician(s) caring for patient believed that immediate renal-replacement therapy was mandated. After fulfilling the above inclusion/exclusion criteria, the study team was to speak to the ICU and/or nephrology attending physician and ask if he/she agreed with statement: "Renal-replacement therapy must be initiated immediately for this patient." If the answer was "Yes", the patient was excluded but could have been re-screened for eligibility, if applicable.
10. Clinician(s) caring for patient believed that deferral of renal-replacement therapy was mandated. After fulfilling the above inclusion/exclusion criteria, the study team was to speak to the ICU and/or nephrology attending physician and ask if he/she agreed with statement: "Renal-replacement therapy must be deferred for this patient." If the answer was "Yes", the patient was excluded, but could have been re-screened for eligibility.
A negative answer by all of the relevant clinicians to exclusions 9 and 10 formally transitioned the patient's status from <i>provisional</i> to <i>full</i> eligibility. The time of full eligibility was noted and marked the beginning of a 12-hour period, during which informed consent must have been obtained (or alternate consent approaches invoked) and the patient randomized. If consent could not be secured during the 12 hours after full eligibility was established, the patient was no longer eligible for participation.

<b>Table S3: Pre-planned exploratory analyses of death at 90-days (primary outcome) and renal-replacement therapy dependence at 90-days (secondary outcome).</b>
<b>Primary Outcome (Death at 90 days)</b>
1. “Adjusted” analysis – We performed an adjusted logistic regression analysis of the primary outcome and report this as an adjusted-odds ratio (95% CI), adjusting for baseline characteristics (age, sex, baseline eGFR, Simplified Acute Physiology Score [SAPS] II score at enrollment, surgical admission, sepsis). Continuous variables (age, eGFR, SAPS II score) were modelled using restricted cubic splines with 4 knots to accommodate the possibility of non-linear relationships with the log-odds of death.
2. “As-Treated” population analysis – We analyzed the effect of the treatment strategy in an “as-treated” population, defined by analyzing patients according to the renal-replacement therapy initiation strategy that was delivered (e.g., patients allocated to the accelerated-strategy who did not receive renal-replacement therapy or started renal-replacement therapy beyond 12 hours from full eligibility were analyzed as “standard- strategy”; and patients allocated to the standard-strategy who started renal-replacement therapy within 12 hours of full eligibility were analyzed as “accelerated-strategy”).
3. Heterogeneity of treatment effect analysis – To assess for heterogeneity of treatment effect of the treatment-strategy on the primary outcome by illness acuity, death at 90-days was analyzed across baseline predicted risk of death using the SAPS II score, by use of an interaction term between treatment-strategy and SAPS II score in the fully adjusted model.
<b>Secondary Outcome (Renal-replacement therapy dependence at 90-days)</b>
The proportion of survivors who were renal-replacement therapy dependent at 90-days required special consideration, as the non-inclusion of patients who died may have obviated the intergroup balance afforded by randomization. We undertook two complementary approaches to address this.
1. Inverse probability weighting – We developed a logistic regression model for the primary outcome to estimate the probabilities of survival at 90-days. We then used the reciprocals of these probabilities as weights in a logistic regression analysis for renal-replacement therapy dependence at 90-days.
2. Multinomial regression – We developed a multi-nominal model to jointly consider the following states: dead at 90-days, alive at 90-days and receiving renal-replacement therapy, and alive at 90-days and free of renal-replacement therapy.

<b>Table S4: Summary of reasons for exclusion of patients randomized and found to be non-eligible.</b>			
<b>Randomized Non-Eligible</b>	<b>Total</b>	<b>Accelerated-Strategy</b>	<b>Standard-Strategy</b>
<b>Total</b>	<b>50</b>	<b>31</b>	<b>19</b>
<b>Did not fulfill all inclusion criteria</b>	<b>32</b>	<b>21</b>	<b>11</b>
<b>Met an exclusion criterion</b>	<b>18</b>	<b>10</b>	<b>8</b>
<b>Exclusion 1 (Serum potassium &gt;5.5 mmol/L)</b>	1	1	0
<b>Exclusion 2 (Serum bicarbonate &lt;15 mmol/L)</b>	9	5	4
<b>Exclusion 3 (Drug overdose or toxin)</b>	0	--	--
<b>Exclusion 4 (Lack of commitment to RRT)</b>	0	--	--
<b>Exclusion 5 (Any RRT within prior 2 months)</b>	1	0	1
<b>Exclusion 6 (Kidney transplant within prior year)</b>	0	--	--
<b>Exclusion 7 (Advanced chronic kidney disease)</b>	4	2	2
<b>Exclusion 8 (Obstruction, GN, vasculitis, TMA)</b>	3	2	1
Abbreviations: RRT = renal-replacement therapy GN = glomerulonephritis; TMA = thrombotic microangiopathy			

<b>Table S5: Expanded baseline characteristics by allocated treatment-strategy.</b>				
<b>Characteristic</b>	<b>Accelerated-strategy</b>	<b>Data available</b>	<b>Standard-strategy</b>	<b>Data available</b>
Age – yr	64.6 ± 14.3	1465	64.7 ± 13.4	1462
Female sex – no. (%)	470 (32.1)	1465	467 (31.9)	1462
Weight – kg	88.0 ± 27.4	1461	88.0 ± 25.1	1459
Baseline serum creatinine <sup>a</sup> – mg/dl	1.4 ± 1.0	1465	1.3 ± 1.0	1462
Baseline eGFR <sup>b</sup> – mL/min/1.73m <sup>2</sup>	66.0 ± 29.8	1465	67.3 ± 29.8	1462
Clinical Frailty Scale score	3 (2 to 5)	1163	3 (2 to 5)	1142
Clinical Frailty Scale score > 4 – no. (%)	308 (26.5)	1163	308 (27.0)	1142
EQ-VAS	59.0 ± 26.7	756	60.4 ± 26.1	738
<b>Pre-existing conditions – no. (%)</b>				
Chronic kidney disease – (eGFR <60 mL/min/1.73m <sup>2</sup> )	658 (44.9)	1465	626 (42.8)	1462
eGFR – mL/min/1.73m <sup>2</sup>		1465		1462
≥ 60	807 (55.1)		836 (57.2)	
45-59	257 (17.5)		260 (17.8)	
30-44	230 (15.7)		183 (12.5)	
< 30	171 (11.7)		183 (12.5)	
Hypertension	814 (55.6)	1465	823 (56.3)	1461
Diabetes mellitus	439 (30.0)	1465	459 (31.4)	1462
Heart failure	204 (13.9)	1465	204 (14.0)	1461
Coronary artery disease	320 (21.8)	1465	328 (22.5)	1461
Liver disease	172 (11.7)	1465	165 (11.3)	1461
Metastatic cancer	77 (5.3)	1465	84 (5.7)	1462
Hematologic malignancy	87 (5.9)	1465	83 (5.7)	1462
HIV/AIDS	13 (0.9)	1465	13 (0.9)	1462
<b>Admission category – no. (%)</b>		1465		1462
Scheduled surgery	207 (14.1)		184 (12.6)	
Unscheduled surgery	285 (19.5)		289 (19.8)	
Medical	973 (66.4)		989 (67.6)	
<b>Hospital-acquired risk factors for AKI in preceding 7 days – no. (%)</b>				
Cardiopulmonary bypass	112 (7.6)	1465	118 (8.1)	1462
Aortic aneurysm repair	71 (4.8)	1465	74 (5.1)	1461
Other vascular surgery	76 (5.2)	1465	77 (5.3)	1462
Major trauma	62 (4.2)	1465	55 (3.8)	1462
Obstetric complications	5 (0.3)	1465	5 (0.3)	1462
Radiocontrast exposure	382 (26.1)	1463	375 (25.7)	1460
Receipt of an aminoglycoside	154 (10.5)	1463	148 (10.2)	1458
Receipt of amphotericin B	9 (0.6)	1464	12 (0.8)	1460
<b>Characteristics at enrollment</b>				
Sepsis – no. (%)	855 (58.4)	1465	834 (57.0)	1462
Septic Shock – no. (%)	640 (43.7)	1465	643 (44.0)	1462
SAPS II score <sup>c</sup>	58.1 ± 17.4	1465	59.4 ± 17.4	1462
SOFA score <sup>d</sup>	11.6 ± 3.6	1465	11.8 ± 3.6	1462
<b>Physiological support and interventions – no. (%)</b>				



<b>Mechanical ventilation</b>	1103 (75.3)	1465	1148 (78.5)	1462
<b>Vasoactive support</b>	1008 (68.8)	1465	1052 (72.0)	1462
<b>Diuretic therapy</b>	502 (34.3)	1465	508 (34.8)	1461
<b>Enteral nutrition</b>	525 (35.8)	1465	559 (38.2)	1462
<b>Total parenteral nutrition</b>	182 (12.4)	1465	167 (11.4)	1462
<b>Physiological parameters</b>				
<b>Heart rate – beats/min</b>	107 ± 27	1463	108 ± 26	1459
<b>Systolic blood pressure – mmHg</b>	102 ± 28	1462	101 ± 28	1457
<b>Temperature – degrees Celsius</b>	37.4 ± 1.3	1458	37.5 ± 1.4	1458
<b>Glasgow coma scale</b>	9.2 ± 4.9	1432	8.8 ± 5.0	1417
<b>Urine output – mL/24hr</b>	450 (190 to 945)	1415	478 (187 to 975)	1420
<b>Oliguria or anuria<sup>e</sup>– no. (%)</b>	647 (45.7)	1415	618 (43.5)	1420
<b>Cumulative fluid balance<sup>f</sup> – mL</b>	2581 (820 to 5362)	1378	2819 (836 to 5603)	1360
<b>Percent Fluid overload<sup>g</sup> – no. (%)</b>	3.1 (1.0 to 6.6)	1374	3.2 (0.9 to 6.8)	1357
<b>Laboratory parameters</b>				
<b>Hemoglobin – g/dL</b>	10.0 ± 2.3	1457	10.0 ± 3.0	1451
<b>White blood cell count – cells x 10<sup>9</sup>/L</b>	18.4 ± 20.6	1455	17.8 ± 17.4	1444
<b>Platelets – cells x 10<sup>9</sup>/L</b>	175 ± 122	1455	168 ± 115	1450
<b>Serum bilirubin – mg/dL</b>	2.6 ± 5.2	1269	2.4 ± 4.3	1277
<b>Arterial pH</b>	7.3 ± 0.1	1367	7.3 ± 0.1	1350
<b>Serum sodium – mmol/L</b>	138 ± 7	1465	138 ± 7	1460
<b>Serum creatinine – mg/dL</b>	3.6 ± 1.7	1464	3.4 ± 1.6	1461
<b>Serum potassium – mmol/L</b>	4.5 ± 0.8	1464	4.5 ± 0.8	1461
<b>Serum bicarbonate – mmol/L</b>	19.7 ± 4.7	1437	19.5 ± 4.5	1423
<b>Blood urea nitrogen – mg/dL</b>	60.8 ± 34.3	1382	61.0 ± 33.9	1380

Data are presented as mean ± standard deviation, median (interquartile range) or number (%).

Abbreviations: eGFR = estimated glomerular filtration rate; EQ-VAS = EuroQoL visual analogue scale; HIV = human immunodeficiency virus; AIDS = acquired immunodeficiency syndrome; AKI = acute kidney injury; SAPS = Simplified Acute Physiology Score; SOFA = Sequential Organ Failure Assessment; TPN = total parenteral nutrition.

Data are presented as mean ± standard deviation, median (interquartile range) or number (%).

<sup>a</sup> Baseline serum creatinine was defined as the most recent outpatient serum creatinine obtained during the year preceding the current hospitalization. If this value was not available, the lowest serum creatinine during the current hospitalization was used to establish the baseline serum creatinine.

<sup>b</sup> Baseline eGFR was derived using the Chronic Kidney Disease - Epidemiology equation which incorporates the baseline serum creatinine, age, sex and whether the patient was of African background.

<sup>c</sup> Scores on the SAPS II score range from 0 to 163, with higher scores indicating more severe disease and a higher risk of death.

<sup>d</sup> Scores on the SOFA score range from 0-24, with higher scores indicating more severe disease and a higher risk of death.

<sup>e</sup> Oliguria was defined as urine output <400 mL/24hr. Data expressed as a proportion of patients with urine output available.

<sup>f</sup> Cumulative fluid balance from ICU admission.

<sup>g</sup> Fluid overload defined as cumulative fluid balance from ICU admission divided by earliest recorded weight during the hospitalization times 100 and expressed as a percentage.

**Table S6: Characteristics at renal-replacement therapy initiation.**

	<b>Accelerated-strategy (N=1418)</b>	<b>Patients with available data</b>	<b>Standard-strategy (N=903)</b>	<b>Patients with available data</b>
Time from eligibility to RRT initiation – hours	6.1 (3.9 to 8.8)	1417	31.1 (19.0 to 71.8)	903
Time from randomization to RRT initiation – hours	4.4 (2.7 to 6.6)	1417	29.1 (17.3 to 68.4)	903
Physiological parameters at RRT initiation				
Heart rate – beats/min	94 ± 21	1415	93 ± 20	898
Systolic blood pressure - mmHg	118 ± 23	1414	119 ± 23	897
Respiratory rate – breaths/min	21 ± 7	1410	22 ± 7	894
PaO <sub>2</sub> /FiO <sub>2</sub> ratio	243 ± 110	1375	232 ± 113	873
Urine output in the preceding 24 hours – mL	453 (190 to 973)	1384	350 (100 to 1000)	889
Fluid balance – mL	2714 (872 to 5659)	1328	5893 (2265 to 11068)	829
Laboratory parameters at RRT initiation				
Serum creatinine – mg/dL	3.7 ± 1.7	1414	4.9 ± 2.1	900
Blood urea nitrogen – mg/dL	63.7 ± 49.8	1356	85.3 ± 51.3	869
Serum potassium – mmol/L	4.4 ± 0.7	1409	4.6 ± 0.8	903
Serum bicarbonate – mmol/L	20.6 ± 4.4	1388	19.5 ± 4.7	888
Arterial pH	7.3 ± 0.1	1335	7.3 ± 0.1	843
Hemoglobin – g/dL	9.9 ± 2.2	1399	9.3 ± 1.8	899
SOFA score at RRT initiation	10.9 ± 3.6	1417	12.1 ± 3.6	903
Presence of ≥ 1 Indication for RRT at time of RRT initiation in the standard arm – no. (%)	-		597 (66.1)	
Serum potassium ≥ 6 mmol/L – no. (%)			48 (5.3)	
pH ≤ 7.2 or Bicarbonate ≤ 12 mmol/L – no. (%)	-		150 (16.6)	
PaO <sub>2</sub> /FiO <sub>2</sub> ≤ 200 and clinical perception of volume overload – no. (%)	-		394 (43.6)	
Time from randomization to RRT ≥ 72hrs – no. (%)	-		214 (23.7)	

Data are presented as mean ± standard deviation, median (interquartile range) or number (%).

Abbreviations: RRT = renal replacement therapy; AKI = acute kidney injury; SOFA = sequential organ failure assessment.

<b>Table S7: Characteristics of the initial renal-replacement therapy prescription.</b>				
<b>Characteristic</b>	<b>Accelerated-strategy (N=1418)</b>	<b>Patients with available data</b>	<b>Standard-strategy (N=903)</b>	<b>Patients with available data</b>
<b>RRT modality – no. (%)</b>		1417		880
<b>CRRT</b>	969 (68.4)		621 (70.6)	
<b>IHD</b>	383 (27.0)		223 (25.3)	
<b>SLED</b>	65 (4.6)		36 (4.1)	
<b>Dialysis catheter insertion site – no. (%)</b>		1365		841
<b>Jugular</b>	805 (59.0)		488 (58.0)	
<b>Femoral</b>	519 (38.0)		332 (39.5)	
<b>Subclavian</b>	41 (3.0)		21 (2.5)	
<b>Intermittent RRT duration prescribed</b>				
<b>IHD – hours</b>	4.0 (3.0 to 4.0)	382	4.0 (2.6 to 4.0)	222
<b>SLED – hours</b>	8.0 (6.0 to 8.0)	65	8.0 (7.3 to 8.0)	36
<b>CRRT dose prescribed – mL/kg/hr</b>	28.3 (23.0 to 33.0)	963	28.6 (23.0 to 33.1)	619
<b>Anticoagulation – no. (%)</b>		1417		880
<b>Citrate</b>	639 (45.1)		383 (43.5)	
<b>Heparin</b>	407 (28.7)		260 (29.5)	
<b>None</b>	338 (23.9)		213 (24.2)	
<b>Other</b>	33 (2.3)		24 (2.7)	
<b>Ultrafiltration achieved during first RRT session – mL</b>	360 (0 to 1290)	1389	860 (50 to 2000)	867

Data are presented as mean ± standard deviation, median (interquartile range) or number (%).

Abbreviations: RRT = renal replacement therapy; IHD = intermittent hemodialysis; SLED = slow low efficiency dialysis; CRRT = continuous renal replacement therapy

**Table S8: Summary of pre-planned inverse probability weighted and multinomial analyses for renal-replacement therapy dependence at 90-days.**

<b>Analysis<sup>a</sup></b>	<b>Odds Ratio</b>	<b>95% CI</b>
Renal-replacement therapy-dependence at 90-days		
Unadjusted unweighted	1.82	1.26 to 2.63
Unadjusted weighted	1.71	1.31 to 2.24
Adjusted <sup>b</sup> weighted (IPW)	1.75	1.33 to 2.30
Multinomial analysis comparing accelerated versus standard strategies for each state		
Alive not renal-replacement therapy dependent	-	-
Alive and renal-replacement therapy dependent	1.82	1.26 to 2.63
Dead	1.05	0.90 to 1.22
Abbreviations: CI = confidence interval; IPW = inverse probability weighting		
<sup>a</sup> Referent group are patients randomized to the standard RRT initiation strategy.		
<sup>b</sup> Adjusted for age, sex, baseline eGFR, SAPS II score, surgical status and sepsis.		

<b>Table S9: Causes of death<sup>a</sup>.</b>		
<b>Cause</b>	<b>Accelerated-strategy (N=640)</b>	<b>Standard-strategy (N=630)</b>
Neurological – no. (%)		
Brain death	6 (0.9)	8 (1.3)
Hypoxic encephalopathy	12 (1.9)	16 (2.5)
Intracranial hemorrhage	6 (0.9)	3 (0.5)
Ischemic stroke	8 (1.3)	4 (0.6)
Other	9 (1.4)	8 (1.3)
Cardiovascular – no. (%)		
Primary arrhythmia	30 (4.7)	28 (4.5)
Refractory cardiogenic shock	34 (5.3)	36 (5.7)
Cardiac tamponade	3 (0.5)	3 (0.5)
Hypovolemia (bleeding)	17 (2.7)	13 (2.1)
Septic shock	195 (30.5)	176 (28.0)
Massive pulmonary embolism	5 (0.8)	1 (0.2)
Anaphylaxis	1 (0.2)	1 (0.2)
Other	114 (17.8)	110 (17.5)
Respiratory – no. (%)		
Refractory hypoxia due to ARDS	40 (6.3)	46 (7.3)
COPD	6 (0.9)	9 (1.4)
Asthma	0	2 (0.3)
Pulmonary hemorrhage	0	2 (0.3)
Pneumothorax	2 (0.3)	0
Other	86 (13.4)	82 (13.0)
Metabolic – no. (%)		
Hypoglycemia	0	0
Hyperkalemia	0	4 (0.6)
Hypothermia	0	0
Liver failure	22 (3.4)	24 (3.8)
Other	44 (6.9)	54 (8.6)
Abbreviations: ARDS = acute respiratory distress syndrome; COPD = chronic obstructive pulmonary disease.		
<sup>a</sup> Cause of death not available for 12 patients, 3 patients in the accelerated-strategy and 9 patients in the standard-strategy.		
Data were available on withdrawal of life-sustaining therapy for 1270/1282 patients (99.1%) who died: 412 (64.4%) in the accelerated-strategy and 391 (61.2%) in the standard-strategy.		

<b>Table S10. All-cause mortality at 90-days across pre-specified subgroups.</b>			
	<b>Accelerated-strategy no. deaths/total</b>	<b>Standard-strategy no. deaths/total</b>	<b>Odds Ratio (95% CI)</b>
<b>Total Population</b>	643/1465	639/1462	1.01 (0.87 to 1.17)
<b>Patient sex</b>			
<b>Female</b>	191/470	207/467	0.91 (0.69 to 1.20)
<b>Male</b>	452/995	432/995	1.12 (0.93 to 1.36)
<b>Patients with eGFR &lt; 45 ml/min/1.73m<sup>2</sup></b>			
<b>Yes</b>	184/401	150/365	1.26 (0.93 to 1.71)
<b>No</b>	459/1064	489/1097	0.99 (0.82 to 1.18)
<b>Patients with SAPS II score &gt; 58</b>			
<b>Yes</b>	387/701	403/751	1.08 (0.87 to 1.34)
<b>No</b>	256/764	236/711	1.02 (0.81 to 1.28)
<b>Patient surgical status</b>			
<b>Medical</b>	458/973	483/989	0.99 (0.82 to 1.19)
<b>Surgical</b>	185/492	156/473	1.20 (0.91 to 1.59)
<b>Patients with sepsis</b>			
<b>Yes</b>	392/855	402/834	0.95 (0.78 to 1.17)
<b>No</b>	251/610	237/628	1.21 (0.95 to 1.54)
<b>Geographic region</b>			
<b>North America</b>	231/497	225/497	1.08 (0.83, to1.42)
<b>Europe</b>	254/574	260/572	1.00 (0.78 to 1.29)
<b>Australia/New Zealand</b>	91/275	86/278	1.12 (0.77 to 1.64)
<b>Asia/South America</b>	67/119	68/115	0.94 (0.53 to 1.68)

Abbreviations: GFR = glomerular filtration rate; SAPS = Simplified Acute Physiology Score.


<b>Table S11. All-cause mortality at 90-days across participating countries.</b>			
<b>Country (no. sites)</b>	<b>Accelerated-strategy (N=1465) no. deaths (%)</b>	<b>Standard-strategy (N=1462) no. deaths (%)</b>	<b>Odds Ratio (95% CI)</b>
<b>Total Population</b>	643 (43.9)	639 (43.7)	1.01 (0.87 to 1.17)
<b>Australia (16)</b>			
<b>Yes</b>	63 (32.6)	59 (29.8)	1.15 (0.73 to 1.80)
<b>No</b>	580 (45.6)	580 (45.9)	1.04 (0.88 to 1.22)
<b>Austria (4)</b>			
<b>Yes</b>	16 (61.5)	10 (40.0)	2.88 (0.85 to 9.73)
<b>No</b>	627 (43.6)	629 (43.8)	1.03 (0.88 to 1.21)
<b>Belgium (1)</b>			
<b>Yes</b>	13 (59.1)	9 (39.1)	2.89 (0.82 to 10.24)
<b>No</b>	630 (43.7)	630 (43.8)	1.04 (0.89 to 1.21)
<b>Brazil (1)</b>			
<b>Yes</b>	4 (100)	2 (50)	-
<b>No</b>	639 (43.7)	637 (43.7)	1.05 (0.90 to 1.23)
<b>Canada (43)</b>			
<b>Yes</b>	195 (44.9)	191 (43.7)	1.08 (0.82 to 1.44)
<b>No</b>	448 (43.5)	448 (43.7)	1.04 (0.86 to 1.25)
<b>China (14)</b>			
<b>Yes</b>	63 (54.8)	66 (59.5)	0.90 (0.50 to 1.61)
<b>No</b>	580 (43.0)	573 (42.4)	1.06 (0.90 to 1.25)
<b>Finland (3)</b>			
<b>Yes</b>	4 (16.0)	7 (26.9)	0.50 (0.12 to 2.05)
<b>No</b>	639 (44.4)	632 (44.0)	1.06 (0.91 to 1.2)

<b>France (29)</b>			
Yes	176 (47.4)	191 (50.8)	0.88 (0.65 to 1.20)
No	467 (42.7)	448 (41.3)	1.12 (0.94 to 1.35)
<b>Germany (2)</b>			
Yes	9 (60.0)	6 (42.9)	2.89 (0.59 to 14.27)
No	634 (43.7)	633 (43.7)	1.04 (0.89 to 1.22)
<b>Ireland (1)</b>			
Yes	0	0	-
No	643 (43.7)	639 (43.7)	1.05 (0.90 to 1.23)
<b>Italy (2)</b>			
Yes	1 (100)	1 (50)	-
No	642 (43.9)	638 (43.7)	1.05 (0.90 to 1.23)
<b>New Zealand (9)</b>			
Yes	28 (34.1)	27 (33.8)	1.02 (0.51 to 2.02)
No	615 (44.5)	612 (44.3)	1.06 (0.90 to 1.24)
<b>Switzerland (2)</b>			
Yes	7 (35.0)	8 (44.4)	0.76 (0.19 to 2.98)
No	636 (44.0)	631 (43.7)	1.06 (0.90 to 1.24)
<b>United Kingdom (35)</b>			
Yes	28 (30.4)	28 (32.2)	1.11 (0.57 to 2.14)
No	615 (44.8)	611 (44.4)	1.05 (0.90 to 1.23)
<b>United States (6)</b>			
Yes	36 (57.1)	34 (56.7)	1.03 (0.48 to 2.20)
No	607 (43.3)	605 (43.2)	1.05 (0.90 to 1.24)




## 6. Supplemental Figures:

Figure S1: Screening and recruitment algorithm.



**Figure S2.** Participant flow diagram.




Legend:


<sup>a</sup> Excluded patients may have met more than 1 criterion.

<sup>b</sup> Confirmed or suspicion of alternative etiology for acute kidney injury such as obstruction, glomerulonephritis, vasculitis, thrombotic microangiopathy.

**Figure S3:** Time to renal-replacement therapy initiation accounting for the competing risk of death.



**Figure S4:** Kaplan-Meier survival estimates of the probability of survival to 90-days including patients lost to follow-up.



**Figure S5.** Heterogeneity of treatment effect by deciles of SAPS II score in fully adjusted model.

